Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals to Host R&D Day on RNAi-Based Therapies
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development Day to discuss its pipeline of RNAi-based therapies on September 14 in New York City . The R&D Day will feature presentations by key opinion leaders (KOLs)
View HTML
Toggle Summary Arrowhead Reports Fiscal 2017 Third Quarter Results
Conference Call and Webcast Today at 4:30 p.m. EDT PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), today announced financial results for its fiscal 2017 third quarter ended June 30, 2017 . The company is hosting a conference call at 4:30 p.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Third Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Thursday, August 3, 2017 , at 4:30 p.m. EDT to discuss its financial results for the fiscal 2017 third quarter ended June 30, 2017 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on June 5, 2017 , eleven new employees were awarded "inducement" grants of options under Rule 5635(c)(4) of the NASDAQ Marketplace
View HTML
Toggle Summary Arrowhead Reports Fiscal 2017 Second Quarter Results
- Conference Call and Webcast Today at 4:30 p.m. EDT PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), today announced financial results for its fiscal 2017 second quarter ended March 31, 2017 . The company is hosting a conference call at 4:30 p.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Wednesday, May 3, 2017 , at 4:30 p.m. EDT to discuss its financial results for the fiscal 2017 second quarter ended March 31, 2017 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals Presents ARC-AAT Clinical Data at The International Liver Congress™
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) presented clinical data from a Phase 1a/1b study of ARC-AAT, the company's prior generation investigational medicine that was being studied for the treatment of liver disease associated with alpha-1 antitrypsin
View HTML
Toggle Summary Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress™
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented clinical data from a Phase 2 study of ARC-520 and a Phase 1/2 study of ARC-521, the company's prior generation investigational medicines that were being studied for the treatment of chronic hepatitis
View HTML
Toggle Summary Arrowhead Pharmaceuticals Announces Presentations at The International Liver Congress™
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present clinical data on ARC-520, ARC-521, and ARC-AAT, the company's prior generation investigational medicines that were being studied for the treatment of chronic hepatitis B infection
View HTML
Toggle Summary Arrowhead Pharmaceuticals Adopts Stockholder Rights Agreement
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on March 21, 2017 it entered into a stockholder rights agreement in accordance with an authorization and declaration from its board of directors of a dividend distribution of one preferred share
View HTML